AZ-AXWAY
5.8.2020 15:43:07 CEST | Business Wire | Press release
Axway (Euronext: AXW.PA) has been named a Leader in The Forrester Wave™: API Management Solutions Q3 2020 , receiving the highest possible score across eight criteria.
Forrester included 15 vendors in this assessment, grouping by Leaders, Strong Performers, Contenders, and Challengers. Axway received the highest score possible in the product vision, and planned enhancements criteria, with Forrester noting “It had among the best articulations of future API management priorities and products plans...”
“Axway can integrate with and support multiple cloud platforms, multiple integration patterns, as well as API management solutions from other vendors. I am proud that what we consider to be Axway’s vision centered around an Open Platform is being recognized in the market,” said Axway CEO Patrick Donovan. “Our strategy helps customers securely and cost-effectively unlock value to create brilliant business outcomes and customer experiences. Our customers use AMPLIFY API Management to lay foundations for transformation and new business opportunities.”
(See the customer case stories of PermataBank and BNP Paribas Personal Finance.)
According to the report: “Axway customers can benefit from its long-standing B2B product line, including EDI, managed file transfer, and trading partner management, as well as strategic API help from its Catalyst team.” The report also states: “...Axway’s solution was strong in API design and proxy creation, attack protection, microservices support, and organizations as API users.”
“In addition, Axway’s service mesh integration and support for non-Axway gateways (e.g., Amazon API Gateway) extend the solution’s reach and address combined API and microservices strategies,” continues the report. “The solution has a strong messaging gateway and SaaS gateway, embeds Stoplight’s rich API design tool, and features integration platform technology.”
Read more about why Axway was named a Leader in The Forrester Wave™: API Management Solutions Q3 2020.
Click here to view the complete report.
¹The Forrester Wave™: API Management Solutions, Q3 2020, Forrester Research, Inc., August 4, 2020
About Axway
Axway gives heritage IT infrastructure new life, helping more than 11,000 customers worldwide build on what they already have to invent their digital journeys, add new business capabilities, and drive growth ambitions. With the future-proof AMPLIFY™ enterprise integration platform – an innovative combination of APIs, MFT, B2B integration, content services, cloud, communities, and digital ecosystems – we guide continuous innovation and enhance the customer experience faster and more securely than ever before. In business for more than 20 years, Axway (Euronext: AXW.PA) employs over 1,800 people in 18 countries. Learn more at www.axway.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200805005641/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom